Sciencepharma Sp. z o.o
3 products tracked · names used in filings: Sciencepharma Sp. z o.o
Upcoming milestones
Mon 18 Jan 2027🇪🇺 Expected EC decisionestimatein 65 days
Garzulys (insulin aspart): expected EC decision
Estimated as CHMP opinion (2026-11-12) + 67 days, the standard Commission decision period. Not an official date. · Sciencepharma Sp. z o.o · source
Recent milestones
Thu 12 Nov 2026🇪🇺 CHMP positive opinion
Garzulys (insulin aspart): CHMP positive opinion
Sciencepharma Sp. z o.o; Biosimilar · source
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | Garzulys insulin aspart | Opinion | |
| 🇪🇺 | Bildyos denosumab | Authorised | 2025-09-17 |
| 🇪🇺 | Bilprevda denosumab | Authorised | 2025-09-17 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.